Carl Klutke, MD
Urology · Asheville, NCNPI 1003832221
Payments from drug & device makers
Across 177 payments — averaging $62.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$7K
- Boston Scientific$424
- Myriad Genetic Laboratories, Inc.$333
- Astellas Pharma US Inc$303
- Medtronic$256
- Sanara Medtech Inc.$237
- plus $2K from 31 others
Across 6 payments — averaging $1062.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$6K
What the payments were for
- Speaking & faculty fees$4,72543%
- Travel & lodging$9388%
- Food & beverage$5,21847%
- Education$2312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 49 | $7,280 |
| Boston Scientific | 10 | $424 |
| Myriad Genetic Laboratories, Inc. | 10 | $333 |
| Astellas Pharma US Inc | 10 | $303 |
| Medtronic(2 entities) | 7 | $256 |
| Sanara Medtech Inc. | 2 | $237 |
| Axonics, Inc. | 5 | $228 |
| AbbVie(2 entities) | 9 | $197 |
| KARL Storz Endoscopy-america | 3 | $195 |
| Bayer | 2 | $159 |
| Johnson & Johnson | 7 | $148 |
| Endo Pharmaceuticals Inc. | 6 | $139 |
| Merck | 4 | $134 |
| Sumitomo Pharma America, Inc. | 7 | $129 |
| 180 Medical, Inc. | 5 | $124 |
| Endo USA, Inc. | 5 | $100 |
| Rochester Medical Corporation | 2 | $86 |
| Urogen Pharma, Inc. | 3 | $70 |
| Olympus America Inc. | 3 | $60 |
| Halozyme Inc | 3 | $50 |
| Convatec Inc. | 2 | $48 |
| Urovant Sciences Inc | 2 | $44 |
| Myovant Sciences Inc. | 3 | $44 |
| Tolmar, Inc. | 2 | $40 |
| Laborie Medical Technologies Corp. | 2 | $36 |
| Antares Pharma, Inc. | 2 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $30 |
| Baxter Healthcare | 1 | $29 |
| Hollister Incorporated | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Elutia, Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $16 |
| Calyxo, Inc. | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $13 |
| Photocure Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$4,725
- TITAN$1,286
- CellerateRx$237
- Xofigo$134
- SPEEDICATH$127
- REZUM$119
How this compares
$11,112 in reported general payments places this provider in the 80th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 20 | $302,765 |
| MyrbetriqMirabegron | 176 | $162,639 |
| OrgovyxRelugolix | 34 | $91,450 |
| GemtesaVibegron | 77 | $82,576 |
| Tamsulosin Hcl | 708 | $9,991 |
| Finasteride | 305 | $4,968 |
| Oxybutynin Chloride | 138 | $3,214 |
| Estradiol | 54 | $2,977 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $2,961 |
| Potassium Citrate ErPotassium Citrate | 19 | $2,536 |
| Methenamine Hippurate | 32 | $2,270 |
| NitrofurantoinNitrofurantoin Macrocrystal | 87 | $2,005 |
| Solifenacin Succinate | 26 | $1,825 |
| Dutasteride | 25 | $882 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $148 | $302,76520 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $129 | $174,025111 claims |
| Astellas Pharma US IncMyrbetriq | $303 | $162,639176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 urology providers in North Carolina.
Other urology in Asheville
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
- Scott MacdiarmidGreensboro$882K
- Glenn PremingerDurham$736K
- Jonathan HamiltonGreenville$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.